Drug makers are crowding into the arthritis business. But, to grab a share of that giant market, they’ll have to stand up against Abbott’s blockbuster treatment Humira.
June 9th, 2012
Christopher Weaver Drug makers are crowding into the arthritis business. But, to grab a share of that giant market, they’ll have to stand up against Abbott’s blockbuster treatment Humira.


